caffeine has been researched along with Schizophrenia in 67 studies
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clozapine is an atypical antipsychotic drug and displays efficacy in 30% to 60% of patients with schizophrenia who do not respond to traditional antipsychotics." | 9.09 | CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. ( Afra, P; Albers, LJ; Collins, EJ; Kalow, W; Kennedy, JL; Ozdemir, V; Posner, P; Reist, C; Roy, R; Tang, BK; Walkes, W, 2001) |
| "Cerebral blood flow (CBF) measurements and mental status examinations were performed before and 30 min after oral administration of 250 mg of caffeine or a placebo given under double-blind conditions, in two groups of patients with schizophrenia." | 9.06 | Caffeine-induced cerebral blood flow changes in schizophrenia. ( Mathew, RJ; Tant, S; Wilson, WH, 1986) |
| "There are numerous reports of increased use of both caffeine and nicotine in schizophrenia." | 8.84 | Use of caffeine and nicotine in people with schizophrenia. ( Gandhi, KK; Williams, JM, 2008) |
| "Although the database is small and not completely consistent, it appears that patients with schizophrenia have high caffeine intakes." | 8.80 | Caffeine and schizophrenia. ( Holtzman, S; Hughes, JR; McHugh, P, 1998) |
| "Our study is the first study in the literature that examines the relationship between caffeine and cigarette intake and SANS and SAPS scales in patients with schizophrenia." | 8.31 | Is there a Relationship Between Caffeine Intake and Smoking and Positive and Negative Symptom Severity in Schizophrenia? ( Baltaci, E; Egeli, A; Hakyemez Geylani, G; Han Almis, B; Tekin, A, 2023) |
| "This study further explores the association between schizophrenia and caffeine use by combining two prior published Spanish samples (250 schizophrenia outpatients and 290 controls from the general population) with two Spanish long-term inpatient samples from the same hospital (145 with schizophrenia and 64 with other severe mental illnesses)." | 7.81 | Caffeine consumption in a long-term psychiatric hospital: Tobacco smoking may explain in large part the apparent association between schizophrenia and caffeine use. ( Armas Barbazán, C; Arrojo-Romero, M; de Leon, J; Diaz, FJ; Gurpegui, M; Jurado, D; López-Moriñigo, JD; Martínez-Ortega, JM; Ramos-Ríos, R, 2015) |
| "Fixed oral doses of clozapine produce up to 45-fold interindividual variability among its serum levels in patients with treatment-resistant schizophrenia." | 7.79 | Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. ( Jacob, KS; Jacob, M; Kuruvilla, A; Poonkuzhali, B; Rajkumar, AP, 2013) |
| "Previous studies of high dietary caffeine intake in individuals with schizophrenia have not demonstrated biological evidence of higher intake or controlled smoking behavior." | 7.76 | Higher serum caffeine in smokers with schizophrenia compared to smoking controls. ( Benowitz, NL; Galazyn, M; Gandhi, KK; Menza, M; Williams, JM, 2010) |
| "Cigarette smoking and caffeine use are established and problematic drug-use behaviors in people with schizophrenia." | 7.75 | Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia. ( Adolfo, AB; AhnAllen, CG; Tidey, JW, 2009) |
| " The aim of this study was to evaluate the effect of subchronic caffeine treatment on MK-801-induced hyperlocomotion, ataxia and cognitive deficits, as well as amphetamine-induced hyperlocomotion in mice." | 7.73 | Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice. ( Dall'Igna, OP; de Oliveira, RV; Lara, DR; Neto, PF; Santos Gomes, MW; Schuh, JF; Souza, DO; Tort, AB, 2005) |
| "According to the literature, there is an association between schizophrenia and caffeine consumption, but it is not clear whether schizophrenia is associated with either higher prevalence of daily caffeine intake or the amount consumed." | 7.73 | Fewer but heavier caffeine consumers in schizophrenia: a case-control study. ( Aguilar, MC; de Leon, J; Diaz, FJ; Gurpegui, M; Jurado, D; Martínez-Ortega, JM; Quintana, HM, 2006) |
| "Community-dwelling schizophrenia patients consume significantly more caffeine and nicotine than US population comparisons." | 7.73 | Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. ( Brar, JS; Ganguli, R; Strassnig, M, 2006) |
| "Several studies suggest that caffeine intake is high in patients with schizophrenia and a few of them suggest that caffeine may contribute to schizophrenia symptomatology." | 7.72 | Caffeine intake in outpatients with schizophrenia. ( Aguilar, MC; de Leon, J; Diaz, FJ; Gurpegui, M; Martínez-Ortega, JM, 2004) |
| "Adenosine A (2A) receptors have been implicated in the pathophysiology of schizophrenia by clinical, anatomical, biochemical and genetic studies." | 7.72 | Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. ( Brenner, M; Danielczyk, W; Deckert, J; Durany, N; Jellinger, K; Paulus, W; Ransmayr, G; Riederer, P; Tatschner, T; Zöchling, R, 2003) |
| "In a previous paper, I have proposed that the deficiency of an endogenous caffeine-like substance is the underlying pathogenic mechanism in schizophrenia (1)." | 7.68 | Exploring the role of an endogenous caffeine-like substance in the pathogenesis of schizophrenia. ( Missak, SS, 1991) |
| "Schizophrenia is a common psychiatric disorder which affects approximately 1% of the population worldwide." | 6.72 | Caffeine consumption and schizophrenia: A highlight on adenosine receptor-independent mechanisms. ( Huang, L; Sperlágh, B, 2021) |
| "Caffeine, 10 mg/kg, was administered to 13 schizophrenic patients in a double-blind placebo-controlled study of its behavioral effects." | 6.67 | Effects of the acute administration of caffeine in patients with schizophrenia. ( Hommer, D; Kelsoe, J; Lucas, PB; Pato, C; Pickar, D; Rapaport, M, 1990) |
| "As caffeine has been shown to selectively increase dopaminergic neurotransmission in mesocortical neurons, further study utilizing dopamine agonists during SPEM in schizophrenic patients is warranted." | 6.66 | Smooth pursuit eye movements in schizophrenia: effects of neuroleptic treatment and caffeine. ( Clem, T; Hommer, DW; Litman, RE; Pato, CN; Pickar, D; Rapaport, MH, 1989) |
| "Individuals with schizophrenia use twice as much caffeine on average when compared to healthy controls." | 5.51 | Alteration of Resting Electroencephalography by Acute Caffeine Consumption in Early Phase Psychosis. ( Anderson, TJ; Fisher, DJ; McKearney, KJ; N Bissonnette, J; Tibbo, PG, 2022) |
| "The high prevalence of substance use, e." | 5.29 | Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia. ( Deviney, S; Hamera, E; Schneider, JK, 1995) |
| "Clozapine is an effective atypical antipsychotic drug applied in the treatment of resistant schizophrenia." | 5.10 | CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. ( Doude van Troostwijk, LJ; Guchelaar, HJ; Koopmans, RP; Vermeulen, HD, 2003) |
| "Clozapine is an atypical antipsychotic drug and displays efficacy in 30% to 60% of patients with schizophrenia who do not respond to traditional antipsychotics." | 5.09 | CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. ( Afra, P; Albers, LJ; Collins, EJ; Kalow, W; Kennedy, JL; Ozdemir, V; Posner, P; Reist, C; Roy, R; Tang, BK; Walkes, W, 2001) |
| "Cerebral blood flow (CBF) measurements and mental status examinations were performed before and 30 min after oral administration of 250 mg of caffeine or a placebo given under double-blind conditions, in two groups of patients with schizophrenia." | 5.06 | Caffeine-induced cerebral blood flow changes in schizophrenia. ( Mathew, RJ; Tant, S; Wilson, WH, 1986) |
| "There are numerous reports of increased use of both caffeine and nicotine in schizophrenia." | 4.84 | Use of caffeine and nicotine in people with schizophrenia. ( Gandhi, KK; Williams, JM, 2008) |
| "Although the database is small and not completely consistent, it appears that patients with schizophrenia have high caffeine intakes." | 4.80 | Caffeine and schizophrenia. ( Holtzman, S; Hughes, JR; McHugh, P, 1998) |
| "Our study is the first study in the literature that examines the relationship between caffeine and cigarette intake and SANS and SAPS scales in patients with schizophrenia." | 4.31 | Is there a Relationship Between Caffeine Intake and Smoking and Positive and Negative Symptom Severity in Schizophrenia? ( Baltaci, E; Egeli, A; Hakyemez Geylani, G; Han Almis, B; Tekin, A, 2023) |
| "A 34 year old male with a history of chronic schizophrenia, who had been managed stably on 400 mg Clozapine for the previous 5 years, changed his dietary behaviour and began consuming caffeine-containing energy drinks over the course of 3 weeks." | 4.02 | Caffeine-clozapine interaction associated with severe toxicity and multiorgan system failure: a case report. ( Peisah, C; Yartsev, A, 2021) |
| "Caffeine and nicotine are widely used by schizophrenia patients and may worsen psychosis and affect antipsychotic therapies." | 3.88 | Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance. ( Avvisati, L; Buonaguro, EF; de Bartolomeis, A; Iasevoli, F; Latte, G; Marmo, F; Tomasetti, C, 2018) |
| "This study further explores the association between schizophrenia and caffeine use by combining two prior published Spanish samples (250 schizophrenia outpatients and 290 controls from the general population) with two Spanish long-term inpatient samples from the same hospital (145 with schizophrenia and 64 with other severe mental illnesses)." | 3.81 | Caffeine consumption in a long-term psychiatric hospital: Tobacco smoking may explain in large part the apparent association between schizophrenia and caffeine use. ( Armas Barbazán, C; Arrojo-Romero, M; de Leon, J; Diaz, FJ; Gurpegui, M; Jurado, D; López-Moriñigo, JD; Martínez-Ortega, JM; Ramos-Ríos, R, 2015) |
| "Nurses in Korea should play an active role in tobacco control for patients with schizophrenia by providing cessation counseling and educating the effect of caffeine use on cigarette consumption, while tailoring the service to gender differences found in this study." | 3.79 | Smoking among individuals with schizophrenia in Korea: gender differences. ( Chung, S; Jung, AJ; Kalman, D; Kim, SS; Park, JI; Ziedonis, DM, 2013) |
| "Fixed oral doses of clozapine produce up to 45-fold interindividual variability among its serum levels in patients with treatment-resistant schizophrenia." | 3.79 | Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. ( Jacob, KS; Jacob, M; Kuruvilla, A; Poonkuzhali, B; Rajkumar, AP, 2013) |
| "Previous studies of high dietary caffeine intake in individuals with schizophrenia have not demonstrated biological evidence of higher intake or controlled smoking behavior." | 3.76 | Higher serum caffeine in smokers with schizophrenia compared to smoking controls. ( Benowitz, NL; Galazyn, M; Gandhi, KK; Menza, M; Williams, JM, 2010) |
| "Cigarette smoking and caffeine use are established and problematic drug-use behaviors in people with schizophrenia." | 3.75 | Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia. ( Adolfo, AB; AhnAllen, CG; Tidey, JW, 2009) |
| "According to the literature, there is an association between schizophrenia and caffeine consumption, but it is not clear whether schizophrenia is associated with either higher prevalence of daily caffeine intake or the amount consumed." | 3.73 | Fewer but heavier caffeine consumers in schizophrenia: a case-control study. ( Aguilar, MC; de Leon, J; Diaz, FJ; Gurpegui, M; Jurado, D; Martínez-Ortega, JM; Quintana, HM, 2006) |
| " The aim of this study was to evaluate the effect of subchronic caffeine treatment on MK-801-induced hyperlocomotion, ataxia and cognitive deficits, as well as amphetamine-induced hyperlocomotion in mice." | 3.73 | Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice. ( Dall'Igna, OP; de Oliveira, RV; Lara, DR; Neto, PF; Santos Gomes, MW; Schuh, JF; Souza, DO; Tort, AB, 2005) |
| "Community-dwelling schizophrenia patients consume significantly more caffeine and nicotine than US population comparisons." | 3.73 | Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. ( Brar, JS; Ganguli, R; Strassnig, M, 2006) |
| "Adenosine A (2A) receptors have been implicated in the pathophysiology of schizophrenia by clinical, anatomical, biochemical and genetic studies." | 3.72 | Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. ( Brenner, M; Danielczyk, W; Deckert, J; Durany, N; Jellinger, K; Paulus, W; Ransmayr, G; Riederer, P; Tatschner, T; Zöchling, R, 2003) |
| "Several studies suggest that caffeine intake is high in patients with schizophrenia and a few of them suggest that caffeine may contribute to schizophrenia symptomatology." | 3.72 | Caffeine intake in outpatients with schizophrenia. ( Aguilar, MC; de Leon, J; Diaz, FJ; Gurpegui, M; Martínez-Ortega, JM, 2004) |
| "Our data suggest that at least one drug commonly used to treat schizophrenia (haloperidol) can interfere with the vasodilatory response to NA." | 3.71 | An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. ( Ross, BM; Seeman, M; Turenne, SD, 2001) |
| "This study included 204 patients treated with clozapine for schizophrenia and 192 healthy volunteers receiving a 100 mg oral test dose of caffeine." | 3.70 | Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. ( Bauer, S; Brockmöller, J; Dettling, M; Müller-Oerlinghausen, B; Roots, I; Ruschen, S; Sachse, C; Schley, J, 1999) |
| "In a previous paper, I have proposed that the deficiency of an endogenous caffeine-like substance is the underlying pathogenic mechanism in schizophrenia (1)." | 3.68 | Exploring the role of an endogenous caffeine-like substance in the pathogenesis of schizophrenia. ( Missak, SS, 1991) |
| "Schizophrenia is a common psychiatric disorder which affects approximately 1% of the population worldwide." | 2.72 | Caffeine consumption and schizophrenia: A highlight on adenosine receptor-independent mechanisms. ( Huang, L; Sperlágh, B, 2021) |
| " Seventeen psychiatric patients (9 men and 8 women) were orally administered olanzapine, at a mean +/- standard deviation (SD) dosage of 10 mg/d for all smokers (n = 8) and 7." | 2.71 | Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. ( Benítez, J; Carrillo, JA; Gervasini, G; Herráiz, AG; Ramos, SI; Vizcaíno, S, 2003) |
| "Caffeine, 10 mg/kg, was administered to 13 schizophrenic patients in a double-blind placebo-controlled study of its behavioral effects." | 2.67 | Effects of the acute administration of caffeine in patients with schizophrenia. ( Hommer, D; Kelsoe, J; Lucas, PB; Pato, C; Pickar, D; Rapaport, M, 1990) |
| "As caffeine has been shown to selectively increase dopaminergic neurotransmission in mesocortical neurons, further study utilizing dopamine agonists during SPEM in schizophrenic patients is warranted." | 2.66 | Smooth pursuit eye movements in schizophrenia: effects of neuroleptic treatment and caffeine. ( Clem, T; Hommer, DW; Litman, RE; Pato, CN; Pickar, D; Rapaport, MH, 1989) |
| "Caffeine is an easily available drug which is generally regarded as being safe." | 1.40 | Caffeine intoxication successfully treated by hemoperfusion and hemodialysis. ( Fukasawa, H; Furuya, R; Ishigaki, S; Kinoshita-Katahashi, N; Kumagai, H; Yasuda, H, 2014) |
| "Treatment with risperidone for 4 weeks did not increase daily cigarette consumption or plasma levels of cotinine and caffeine." | 1.35 | Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study. ( Hori, H; Kakihara, S; Nakamura, J; Sugita, A; Ueda, N; Umene-Nakano, W; Yoshimura, R, 2008) |
| "The influence of temperament on substance abuse in schizophrenia is poorly understood, whereas it is known to play an important role in other clinical populations." | 1.30 | Temperament and substance abuse in schizophrenia: is there a relationship? ( Mulder, RT; Sellman, JD; Van Ammers, EC, 1997) |
| "The high prevalence of substance use, e." | 1.29 | Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia. ( Deviney, S; Hamera, E; Schneider, JK, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (25.37) | 18.7374 |
| 1990's | 15 (22.39) | 18.2507 |
| 2000's | 15 (22.39) | 29.6817 |
| 2010's | 12 (17.91) | 24.3611 |
| 2020's | 8 (11.94) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, L | 1 |
| Sperlágh, B | 1 |
| N Bissonnette, J | 1 |
| Anderson, TJ | 1 |
| McKearney, KJ | 1 |
| Tibbo, PG | 1 |
| Fisher, DJ | 1 |
| Rosen, RL | 2 |
| Ramasubramani, RS | 2 |
| Benowitz, NL | 3 |
| Gandhi, KK | 4 |
| Williams, JM | 4 |
| Szoke, A | 1 |
| Richard, JR | 1 |
| Fond, G | 1 |
| Misdrahi, D | 1 |
| Lajnef, M | 1 |
| Aouizerate, B | 1 |
| Boyer, L | 1 |
| Berna, F | 1 |
| Capdevielle, D | 1 |
| André, M | 1 |
| Chereau, I | 1 |
| Clauss-Kobayashi, J | 1 |
| Coulon, N | 1 |
| Dubertret, C | 1 |
| Leignier, S | 1 |
| Llorca, PM | 1 |
| Mallet, J | 1 |
| Passerieux, C | 1 |
| Rey, R | 1 |
| Schorr, B | 1 |
| Urbach, M | 1 |
| Leboyer, M | 1 |
| Pignon, B | 1 |
| Schürhoff, F | 1 |
| Han Almis, B | 1 |
| Tekin, A | 1 |
| Hakyemez Geylani, G | 1 |
| Baltaci, E | 1 |
| Egeli, A | 1 |
| Ramos, AC | 1 |
| de Mattos Hungria, F | 1 |
| Camerini, BA | 1 |
| Suiama, MA | 1 |
| Calzavara, MB | 1 |
| Horvath, G | 1 |
| Adam, G | 1 |
| Tuboly, G | 1 |
| Kekesi, G | 1 |
| Büki, A | 1 |
| Ducza, E | 1 |
| Szűcs, E | 1 |
| Benyhe, S | 1 |
| Benedek, G | 1 |
| Yartsev, A | 1 |
| Peisah, C | 1 |
| de Bartolomeis, A | 1 |
| Iasevoli, F | 1 |
| Marmo, F | 1 |
| Buonaguro, EF | 1 |
| Avvisati, L | 1 |
| Latte, G | 1 |
| Tomasetti, C | 1 |
| Topyurek, M | 1 |
| Tibbo, P | 1 |
| Núñez, C | 2 |
| Stephan-Otto, C | 2 |
| Good, K | 1 |
| Thoma, P | 1 |
| Daum, I | 1 |
| Kim, SS | 1 |
| Chung, S | 1 |
| Park, JI | 1 |
| Jung, AJ | 1 |
| Kalman, D | 1 |
| Ziedonis, DM | 1 |
| Peng, PJ | 1 |
| Chiang, KT | 1 |
| Liang, CS | 1 |
| Ishigaki, S | 1 |
| Fukasawa, H | 1 |
| Kinoshita-Katahashi, N | 1 |
| Yasuda, H | 1 |
| Kumagai, H | 1 |
| Furuya, R | 1 |
| Arrojo-Romero, M | 1 |
| Armas Barbazán, C | 1 |
| López-Moriñigo, JD | 1 |
| Ramos-Ríos, R | 1 |
| Gurpegui, M | 3 |
| Martínez-Ortega, JM | 3 |
| Jurado, D | 2 |
| Diaz, FJ | 3 |
| de Leon, J | 3 |
| Cuevas-Esteban, J | 1 |
| Maria Haro, J | 1 |
| Huerta-Ramos, E | 1 |
| Ochoa, S | 1 |
| Usall, J | 1 |
| Brébion, G | 1 |
| Adolfo, AB | 1 |
| AhnAllen, CG | 1 |
| Tidey, JW | 1 |
| Menza, M | 1 |
| Galazyn, M | 1 |
| BARUK, H | 1 |
| RACINE, M | 1 |
| Tibrewal, P | 1 |
| Dhillon, R | 1 |
| Yoshimura, R | 3 |
| Nakamura, J | 3 |
| Rajkumar, AP | 1 |
| Poonkuzhali, B | 1 |
| Kuruvilla, A | 1 |
| Jacob, M | 1 |
| Jacob, KS | 1 |
| Deckert, J | 1 |
| Brenner, M | 1 |
| Durany, N | 1 |
| Zöchling, R | 1 |
| Paulus, W | 1 |
| Ransmayr, G | 1 |
| Tatschner, T | 1 |
| Danielczyk, W | 1 |
| Jellinger, K | 1 |
| Riederer, P | 1 |
| Carrillo, JA | 2 |
| Herráiz, AG | 2 |
| Ramos, SI | 2 |
| Gervasini, G | 1 |
| Vizcaíno, S | 1 |
| Benítez, J | 2 |
| BRUCK, D | 1 |
| ABELY, P | 1 |
| RICHARDEAU, N | 1 |
| DEDIEU-ANGLADE, G | 1 |
| BENOIT, JC | 1 |
| LYNN, R | 1 |
| GUSHANSKII, EL | 1 |
| PFEIFFER, CC | 1 |
| GOLDSTEIN, L | 1 |
| MURPHREE, HB | 1 |
| SUGERMAN, AA | 1 |
| BAZHIN, EF | 1 |
| Doude van Troostwijk, LJ | 1 |
| Koopmans, RP | 1 |
| Vermeulen, HD | 1 |
| Guchelaar, HJ | 1 |
| Bozikas, VP | 1 |
| Papakosta, M | 1 |
| Niopas, I | 1 |
| Karavatos, A | 1 |
| Mirtsou-Fidani, V | 1 |
| Kakihara, S | 2 |
| Shinkai, K | 1 |
| Matsumoto, C | 1 |
| Goto, M | 1 |
| Kaji, K | 1 |
| Yamada, Y | 1 |
| Ueda, N | 2 |
| Ohmori, O | 1 |
| de Oliveira, RV | 1 |
| Dall'Igna, OP | 1 |
| Tort, AB | 1 |
| Schuh, JF | 1 |
| Neto, PF | 1 |
| Santos Gomes, MW | 1 |
| Souza, DO | 1 |
| Lara, DR | 1 |
| Aguilar, MC | 2 |
| Quintana, HM | 1 |
| Strassnig, M | 1 |
| Brar, JS | 1 |
| Ganguli, R | 1 |
| Brown, GG | 1 |
| Eyler, LT | 1 |
| Umene-Nakano, W | 1 |
| Sugita, A | 1 |
| Hori, H | 1 |
| Hamera, E | 1 |
| Schneider, JK | 1 |
| Deviney, S | 1 |
| Marcus, P | 1 |
| Snyder, R | 1 |
| Zaretsky, A | 1 |
| Rector, NA | 1 |
| Seeman, MV | 1 |
| Fornazzari, X | 1 |
| Vainer, JL | 1 |
| Chouinard, G | 1 |
| Mayo, KM | 1 |
| Falkowski, W | 1 |
| Jones, CA | 1 |
| Donnelly, CL | 1 |
| McEvoy, JP | 1 |
| Wilson, WH | 2 |
| Narasimhachari, N | 1 |
| Van Ammers, EC | 1 |
| Sellman, JD | 1 |
| Mulder, RT | 1 |
| Hughes, JR | 1 |
| McHugh, P | 1 |
| Holtzman, S | 1 |
| Dixon, DA | 1 |
| Fenix, LA | 1 |
| Kim, DM | 1 |
| Raffa, RB | 1 |
| Sachse, C | 1 |
| Ruschen, S | 1 |
| Dettling, M | 1 |
| Schley, J | 1 |
| Bauer, S | 1 |
| Müller-Oerlinghausen, B | 1 |
| Roots, I | 1 |
| Brockmöller, J | 1 |
| Turenne, SD | 1 |
| Seeman, M | 1 |
| Ross, BM | 1 |
| Ozdemir, V | 1 |
| Kalow, W | 1 |
| Posner, P | 1 |
| Collins, EJ | 1 |
| Kennedy, JL | 1 |
| Tang, BK | 1 |
| Albers, LJ | 1 |
| Reist, C | 1 |
| Roy, R | 1 |
| Walkes, W | 1 |
| Afra, P | 1 |
| Rotrosen, J | 1 |
| Miller, AD | 1 |
| Mandio, D | 1 |
| Traficante, LJ | 1 |
| Gershon, S | 1 |
| Mikkelsen, EJ | 1 |
| Goff, DC | 1 |
| Henderson, DC | 1 |
| Amico, E | 1 |
| Missak, SS | 1 |
| Hyde, AP | 1 |
| Lucas, PB | 1 |
| Pickar, D | 2 |
| Kelsoe, J | 1 |
| Rapaport, M | 1 |
| Pato, C | 1 |
| Hommer, D | 1 |
| Litman, RE | 1 |
| Hommer, DW | 1 |
| Clem, T | 1 |
| Rapaport, MH | 1 |
| Pato, CN | 1 |
| Koczapski, A | 1 |
| Paredes, J | 1 |
| Kogan, C | 1 |
| Ledwidge, B | 1 |
| Higenbottam, J | 1 |
| Kirubakaran, V | 1 |
| Holsboer-Trachsler, E | 1 |
| Buol, C | 1 |
| Wiedemann, K | 1 |
| Holsboer, F | 1 |
| Mathew, RJ | 1 |
| Tant, S | 1 |
| Uhde, TW | 1 |
| Bierer, LM | 1 |
| Post, RM | 1 |
| Arushanian, EB | 1 |
| Stoliarov, GV | 1 |
| Tolpyshev, BA | 1 |
| Lugovskiĭ, BK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Caffeine on Cognition in Schizophrenia[NCT02832401] | 24 participants (Actual) | Interventional | 2016-09-02 | Completed | |||
| Clinical Trial of Dipyridamole in Schizophrenia[NCT00349973] | 29 participants (Actual) | Interventional | 2001-05-31 | Completed | |||
| A Randomized Trial Administering Estradiol Patch vs. Placebo Patch as add-on to Antipsychotics in Female Patients Above the Age of 38 With Schizophrenia, Schizoaffective or Schizophreniform Disorder[NCT04093518] | Phase 3 | 100 participants (Anticipated) | Interventional | 2019-12-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Scale for the Assessment of Negative Symptoms (SANS) total score, minus the global items, inappropriate affect, poverty of content of speech, and attention items, used to measure negative symptoms. Mean SANS total score by treatment and week. SANS total score range = 0-85. Higher scores indicate more severe negative symptoms. (NCT00349973)
Timeframe: Baseline and Follow-Up
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (Phase 1/Week 1) | Follow-Up (Phase 4/Week 1) | |
| Dipyridamole | 23.3 | 25.8 |
| Olanzapine | 25.6 | 27.0 |
"The Brief Psychiatric Rating Scale (BPRS) consists of 20 items, with 6 of these items used to assess positive symptom change. The BPRS positive symptom items are: somatic concern, conceptual disorganization, hostility, suspiciousness, hallucinatory behavior, and unusual thought content. Each scale ranges from 1=Not Present to 7=Very Severe. A higher score indicates a more severe positive symptom rating." (NCT00349973)
Timeframe: Baseline and follow-up
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline - Somatic Concern | Follow-Up - Somatic Concern | Baseline - Conceptual Disorganization | Follow-Up - Conceptual Disorganization | Baseline - Hostility | Follow-Up - Hostility | Baseline - Suspiciousness | Follow-Up - Suspiciousness | Baseline - Hallucination | Follow-Up - Hallucination | Baseline - Unusual Thought Content | Follow-Up - Unusual Thought Content | |
| Dipyridamole | 2.222 | 1.60 | 2.667 | 2.00 | 1.222 | 1.00 | 4.11 | 3.000 | 2.67 | 2.600 | 3.111 | 2.800 |
| Olanzapine | 1.400 | 1.00 | 2.600 | 2.00 | 1.200 | 2.00 | 3.40 | 1.500 | 3.80 | 2.500 | 3.400 | 1.500 |
The RBANS is a brief, individually administered test designed to evaluate neuropsychological status of adults, ages 20-89. The 12 subtests measure attention, language, visuospatial/constructional abilities, and immediate and delayed memory. The raw scores from the subtests are scaled together to create index scores, and these are summed for conversion to a total scale score. Higher score equals a better outcome. The total index score range for the RBANS is 40-160. (NCT00349973)
Timeframe: Baseline and Follow-Up
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (Phase 1/Week 1) | Follow-Up (Phase 3/Week 6) | |
| Dipyridamole | 73.00 | 77.40 |
| Olanzapine | 59.00 | 65.00 |
7 reviews available for caffeine and Schizophrenia
| Article | Year |
|---|---|
Caffeine consumption and schizophrenia: A highlight on adenosine receptor-independent mechanisms.
Topics: Antipsychotic Agents; Brain-Gut Axis; Caffeine; Humans; Receptors, Purinergic P1; Schizophrenia | 2021 |
Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings.
Topics: Alcoholism; Brain; Caffeine; Central Nervous System Stimulants; Cognition; Comorbidity; Diagnosis, D | 2013 |
Use of caffeine and nicotine in people with schizophrenia.
Topics: Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Brain; Caffeine; Comorbidity; Cross-Sectional S | 2008 |
RUSSIAN THEORY AND RESEARCH ON SCHIZOPHRENIA.
Topics: Amobarbital; Bromides; Caffeine; Cerebral Cortex; Chlorpromazine; Conditioning, Psychological; Convu | 1963 |
Methodological and conceptual issues in functional magnetic resonance imaging: applications to schizophrenia research.
Topics: Bionics; Biophysics; Brain; Caffeine; Cerebral Cortex; Forecasting; Humans; Magnetic Resonance Imagi | 2006 |
Caffeine and schizophrenia.
Topics: Animals; Antipsychotic Agents; Caffeine; Dopamine; Drug Interactions; Humans; Rats; Schizophrenia; S | 1998 |
Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists.
Topics: Adenosine; Animals; Caffeine; Clinical Trials as Topic; Drug Interactions; Humans; Mutation; Neurotr | 1999 |
10 trials available for caffeine and Schizophrenia
| Article | Year |
|---|---|
Alteration of Resting Electroencephalography by Acute Caffeine Consumption in Early Phase Psychosis.
Topics: Caffeine; Electroencephalography; Humans; Psychotic Disorders; Rest; Schizophrenia | 2022 |
Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Caffeine; Chromatography, High Pressure Liquid; Cytoch | 2003 |
CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients.
Topics: Adult; Algorithms; Antipsychotic Agents; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Female; Human | 2003 |
Caffeine: use and effects in long-stay psychiatric patients.
Topics: Adult; Aged; Anxiety Disorders; Caffeine; Depressive Disorder; Dose-Response Relationship, Drug; Dou | 1993 |
A study of the potential confounding effects of diet, caffeine, nicotine and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Diet; Drug Interactions; GABA Modulators; Homova | 1996 |
CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Dose-Response Relat | 2001 |
Effects of the acute administration of caffeine in patients with schizophrenia.
Topics: Adolescent; Adult; Arousal; Caffeine; Female; Humans; Hydrocortisone; Male; Psychiatric Status Ratin | 1990 |
Smooth pursuit eye movements in schizophrenia: effects of neuroleptic treatment and caffeine.
Topics: Adult; Antipsychotic Agents; Caffeine; Eye Movements; Humans; Saccades; Schizophrenia | 1989 |
Caffeine-induced cerebral blood flow changes in schizophrenia.
Topics: Adult; Caffeine; Cerebrovascular Circulation; Female; Humans; Male; Regional Blood Flow; Schizophren | 1986 |
Caffeine-induced escape from dexamethasone suppression.
Topics: Adult; Caffeine; Clinical Trials as Topic; Coffee; Depressive Disorder; Dexamethasone; Dose-Response | 1985 |
50 other studies available for caffeine and Schizophrenia
| Article | Year |
|---|---|
Caffeine levels and dietary intake in smokers with schizophrenia and bipolar disorder.
Topics: Adult; Bipolar Disorder; Caffeine; Child; Humans; Schizophrenia; Smokers; Smoking; United States | 2023 |
Caffeine levels and dietary intake in smokers with schizophrenia and bipolar disorder.
Topics: Adult; Bipolar Disorder; Caffeine; Child; Humans; Schizophrenia; Smokers; Smoking; United States | 2023 |
Caffeine levels and dietary intake in smokers with schizophrenia and bipolar disorder.
Topics: Adult; Bipolar Disorder; Caffeine; Child; Humans; Schizophrenia; Smokers; Smoking; United States | 2023 |
Caffeine levels and dietary intake in smokers with schizophrenia and bipolar disorder.
Topics: Adult; Bipolar Disorder; Caffeine; Child; Humans; Schizophrenia; Smokers; Smoking; United States | 2023 |
Clinical and pharmacological correlates of caffeine consumption in subjects with schizophrenia - Data from the FACE-SZ cohort.
Topics: Caffeine; Coffee; Humans; Schizophrenia; Smoking; Tea | 2023 |
Is there a Relationship Between Caffeine Intake and Smoking and Positive and Negative Symptom Severity in Schizophrenia?
Topics: Caffeine; Humans; Psychiatric Status Rating Scales; Schizophrenia; Smoking | 2023 |
Potential beneficial effects of caffeine administration in the neonatal period of an animal model of schizophrenia.
Topics: Adenosine; Animals; Animals, Newborn; Caffeine; Disease Models, Animal; Locomotion; Male; Motor Acti | 2020 |
Caffeine - treat or trigger? Disparate behavioral and long-term dopaminergic changes in control and schizophrenia-like Wisket rats.
Topics: Animals; Brain; Caffeine; Dopamine; Humans; Prefrontal Cortex; Rats; Schizophrenia | 2021 |
Caffeine-clozapine interaction associated with severe toxicity and multiorgan system failure: a case report.
Topics: Adult; Antipsychotic Agents; Caffeine; Clozapine; Humans; Male; Schizophrenia | 2021 |
Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance.
Topics: Animals; Brain; Caffeine; Central Nervous System Agents; Cytoskeletal Proteins; Drug Interactions; D | 2018 |
Caffeine effects and schizophrenia: Is there a need for more research?
Topics: Biomedical Research; Caffeine; Central Nervous System Stimulants; Cognition; Humans; Schizophrenia; | 2019 |
Smoking among individuals with schizophrenia in Korea: gender differences.
Topics: Caffeine; Female; Humans; Male; Middle Aged; Republic of Korea; Schizophrenia; Schizophrenic Psychol | 2013 |
Low-dose caffeine may exacerbate psychotic symptoms in people with schizophrenia.
Topics: Caffeine; Central Nervous System Stimulants; Humans; Male; Middle Aged; Psychotic Disorders; Schizop | 2014 |
Caffeine intoxication successfully treated by hemoperfusion and hemodialysis.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Hemoperfusion; Humans; Male; Renal Dialysis; Sch | 2014 |
Caffeine consumption in a long-term psychiatric hospital: Tobacco smoking may explain in large part the apparent association between schizophrenia and caffeine use.
Topics: Adult; Aged; Antipsychotic Agents; Caffeine; Central Nervous System Stimulants; Female; Hospitals, P | 2015 |
Effects of caffeine intake and smoking on neurocognition in schizophrenia.
Topics: Adult; Caffeine; Cognition; Female; Humans; Male; Memory, Short-Term; Middle Aged; Neuropsychologica | 2015 |
Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia.
Topics: Adult; Arousal; Beverages; Caffeine; Comorbidity; Cues; Female; Humans; Male; Middle Aged; Motivatio | 2009 |
Higher serum caffeine in smokers with schizophrenia compared to smoking controls.
Topics: Adult; Antipsychotic Agents; Caffeine; Central Nervous System Stimulants; Female; Humans; Male; Pred | 2010 |
Trial of circulatory treatment of early early dementia with folliculin and caffeine (physiological therapeutics or shock therapeutics?).
Topics: Caffeine; Estrogens; Mental Disorders; Psychotic Disorders; Schizophrenia | 1946 |
Caffeine induced psychotic exacerbation.
Topics: Caffeine; Humans; Male; Middle Aged; Recurrence; Schizophrenia | 2011 |
[Effects of smoking and caffeine on pharmacological treatment for patients with schizophrenia and depression].
Topics: Caffeine; Depression; Drug Interactions; Fluvoxamine; Humans; Risperidone; Schizophrenia; Smoking | 2011 |
Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
Topics: Administration, Oral; Adult; Anticonvulsants; Antipsychotic Agents; Caffeine; Case-Control Studies; | 2013 |
Up-regulation of striatal adenosine A(2A) receptors in schizophrenia.
Topics: Adenosine; Aged; Aged, 80 and over; Antipsychotic Agents; Cadaver; Caffeine; Control Groups; Corpus | 2003 |
[Therapy of schizophrenia].
Topics: Caffeine; Humans; Procaine; Schizophrenia | 1954 |
[Cutaneo-abdominal reflexes in conflict syndromes; caffeine, acecoline, prostigmine & adrenalin control tests; probable anticataionic role of adrenalin in the human].
Topics: Caffeine; Epinephrine; Humans; Neostigmine; Probability; Schizophrenia; Syndrome | 1959 |
[DYNAMICS OF SUBORDINATION AND ADAPTATION IN PATIENTS WITH THE CATATONIC FORM OF SCHIZOPHRENIA WITH CHRONIC UNFAVORABLE DEVELOPMENT].
Topics: Acclimatization; Adaptation, Physiological; Caffeine; Catatonia; Central Nervous System; Chlorpromaz | 1963 |
TIME-SERIES, FREQUENCY ANALYSIS, AND ELECTROGENESIS OF THE EEGS OF NORMALS AND PSYCHOTICS BEFORE AND AFTER DRUGS.
Topics: Amphetamine; Antidepressive Agents; Barbiturates; Biomedical Research; Caffeine; Central Nervous Sys | 1965 |
[APROPOS OF THE USE OF THE AMYTAL-CAFFEINE DISINHIBITION IN CHRONIC SCHIZOPHRENIA IN PSYCHOPATHOLOGICAL STUDY AND PROGNOSTIC EVALUATION OF THERAPY].
Topics: Amobarbital; Caffeine; Humans; Mental Disorders; Prognosis; Psychopathology; Schizophrenia | 1964 |
Smoking impact on CYP1A2 activity in a group of patients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Caffeine; Chi-Square Distribution; Cytochrome P-450 CYP1A2; Enzym | 2004 |
Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Caffeine; Catecholamines; Cen | 2005 |
Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice.
Topics: Adenosine; Amphetamine; Animals; Ataxia; Caffeine; Central Nervous System Stimulants; Cognition; Dis | 2005 |
Caffeine intake in outpatients with schizophrenia.
Topics: Antipsychotic Agents; Caffeine; Central Nervous System Stimulants; Drinking Behavior; Drug Interacti | 2004 |
Fewer but heavier caffeine consumers in schizophrenia: a case-control study.
Topics: Adolescent; Adult; Age Factors; Aged; Alcohol Drinking; Caffeine; Case-Control Studies; Central Nerv | 2006 |
Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia.
Topics: Adult; Body Mass Index; Caffeine; Cross-Sectional Studies; Demography; Feeding Behavior; Female; Fol | 2006 |
Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study.
Topics: Adult; Aged; Antipsychotic Agents; Caffeine; Chromatography, High Pressure Liquid; Coffee; Cotinine; | 2008 |
Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia.
Topics: Adult; Alcoholism; Antipsychotic Agents; Caffeine; Female; Humans; Male; Marijuana Abuse; Middle Age | 1995 |
Reduction of comorbid substance abuse with clozapine.
Topics: Alcohol Drinking; Caffeine; Clozapine; Comorbidity; Diagnosis, Dual (Psychiatry); Ethanol; Humans; S | 1995 |
Current cannabis use and tardive dyskinesia.
Topics: Adult; Alcoholism; Antipsychotic Agents; Caffeine; Dyskinesia, Drug-Induced; Female; Humans; Male; M | 1993 |
Interaction between caffeine and clozapine.
Topics: Adult; Caffeine; Clozapine; Coffee; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hum | 1994 |
Temperament and substance abuse in schizophrenia: is there a relationship?
Topics: Adolescent; Adult; Alcoholism; Caffeine; Coffee; Comorbidity; Exploratory Behavior; Humans; Male; Ma | 1997 |
Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Biological Availability; Biotransformation; Caffeine; Chromatography, H | 1998 |
Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antipsychotic Agents; Caffeine; Case-Control Studies; Centr | 1999 |
An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response.
Topics: Animals; Antipsychotic Agents; Brain; Caffeine; Cerebrovascular Circulation; Disease Models, Animal; | 2001 |
Reduced PGE1 stimulated 3H-cAMP accumulation in platelets from schizophrenics.
Topics: Acute Disease; Adult; Blood Platelets; Caffeine; Chronic Disease; Cyclic AMP; Humans; In Vitro Techn | 1978 |
Caffeine and schizophrenia.
Topics: Acute Disease; Adult; Caffeine; Coffee; Female; Humans; Male; Psychoses, Substance-Induced; Schizoph | 1978 |
Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects.
Topics: Adult; Age Factors; Akathisia, Drug-Induced; Ambulatory Care; Analysis of Variance; Basal Ganglia Di | 1992 |
Exploring the role of an endogenous caffeine-like substance in the pathogenesis of schizophrenia.
Topics: Brain; Caffeine; Female; gamma-Aminobutyric Acid; Humans; Pregnancy; Pregnancy Complications; Recept | 1991 |
Response to "Effects of caffeine on behavior of schizophrenic inpatients".
Topics: Antipsychotic Agents; Caffeine; Dose-Response Relationship, Drug; Humans; Schizophrenia; Schizophren | 1990 |
Effects of caffeine on behavior of schizophrenic inpatients.
Topics: Caffeine; Chronic Disease; Coffee; Humans; Psychiatric Department, Hospital; Psychiatric Status Rati | 1989 |
Hyponatremic coma and elevated serum creatine phosphokinase following excessive caffeine intake.
Topics: Adult; Caffeine; Coma; Creatine Kinase; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Schi | 1986 |
Dexamethasone suppression test in severe schizophrenic illness: effects of plasma dexamethasone and caffeine levels.
Topics: Adult; Caffeine; Dexamethasone; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male | 1987 |
[Effect of caffeine on drug-induced parkinsonism and the caudal reaction of arrest (clinical and experimental study)].
Topics: Animals; Caffeine; Cats; Dose-Response Relationship, Drug; Electric Stimulation; Female; Humans; Mal | 1973 |
[Kulenkampf-Tarnow syndrome, problems of its pathogenesis and treatment].
Topics: Adolescent; Adult; Atropine; Brain Stem; Caffeine; Chlorpromazine; Ephedrine; Humans; Male; Masticat | 1968 |